BROOKS LAB Latest Share Price (BROOKS)
TODAY IN ONE LINE
BROOKS dropped 3.3% on above-average volume (308163.9x avg), lagging Nifty's 0.4% move, with no exchange filing today, suggesting a market-driven move.
With a market cap of ₹180.72 Cr., it trades at a P/E of 8.22. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
BROOKS LAB flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Strong Return on EquityHealthy ROE of 20.0%
- ●Reasonable ValuationTrading at a moderate P/E of 8.2x
- ●High Promoter HoldingPromoters hold 52.6% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.06x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Rising Receivables vs SalesReceivables grew 16.6% outpacing sales growth of 3.9%
Latest BROOKS LAB News
What changed recently?
Recent events, corporate actions, and announcements.
BROOKS LAB valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for BROOKS LAB, framed against the sector median so the premium or discount is obvious at a glance.
BROOKS LAB trades at a P/E of 8.22× and P/B of 1.65×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
BROOKS LAB technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for BROOKS LAB — derived from the latest tape, not yesterday's close.
BROOKS LAB last traded at ₹61.02 with an intraday range of ₹59.13–₹64.7 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹61.02| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 75.24 | +14.22 | +23.31% |
| R3 | 69.67 | +8.65 | +14.18% |
| R2 | 67.19 | +6.17 | +10.11% |
| R1 | 64.10 | +3.08 | +5.05% |
| PIVOT | 61.62 | 0.60 | 0.98% |
| CURRENT | 61.02 | — | — |
| S1 | 58.53 | -2.49 | -4.08% |
| S2 | 56.05 | -4.97 | -8.15% |
| S3 | 52.96 | -8.06 | -13.20% |
| S4 | 47.39 | -13.63 | -22.33% |
BROOKS is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹63.51–₹64.7
Trading Below opening range, showing Bearishness
BROOKS LAB financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for BROOKS LAB — consolidated or standalone — with margins, YoY growth and key ratios inline.
BROOKS LAB reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹180.72 Cr. and reported EPS of ₹4.49.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 83 | 86 ▲ 3.9% |
| Sales Growth YoY %Derived | 3.86% | 3.85% |
| Other Income | 1 | 1 ▲ 32.5% |
| Total Income | 83 | 87 ▲ 4.2% |
| 54 | 51 ▼ 5.6% | |
| Gross ProfitDerived | 28 | 35 ▲ 21.9% |
| Gross Margin %Derived | 34.50% | 40.49% |
| 24 | 28 ▲ 17.5% | |
| EBITDA (Operating Profit)Derived | 5 | 7 ▲ 42.9% |
| OPM %Derived | 5.98% | 8.23% |
| 3 | 2 ▼ 7.8% | |
| Profit Before Tax (PBT) | 3 | 6 ▲ 81.8% |
| 0 | — ▼ 100.0% | |
| Effective Tax %Derived | 5.49% | — |
| Total Profit for Period | -10 | 25 ▲ 346.6% |
| Less: Non-controlling Interests | — | — |
| Net Profit (Owner's PAT)Derived | -10 | 25 ▲ 346.6% |
| Net Profit Margin %Derived | -12.07% | 28.67% |
| PAT Growth YoY %Derived | 49.13% | 346.65% |
| Earnings Per Share (EPS ₹) | -3.38 | 8.34 ▲ 346.7% |
| Diluted Shares Outstanding (Cr) | 3 | 3 ▲ 0.0% |
| Share of Profit from Associates/JVs | -13 | 19 ▲ 244.6% |
| Other Comprehensive Income (Net of Tax) | -0 | -0 ▼ 67.8% |
| Total Expenses (incl. D&A & Interest) | 80 | 81 ▲ 1.1% |
| Material Cost % of RevenueDerived | 56.98% | 57.86% |
| Employee Cost % of RevenueDerived | 15.70% | 17.68% |
| Other Cost % of RevenueDerived | 12.82% | 14.57% |
| Interest Coverage (x)Derived | 3.25x | 6.55x |
| Period | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | 77 | 91 ▲ 17.9% | 63 ▼ 30.6% | 79 ▲ 25.8% | 83 ▲ 3.9% | 86 ▲ 3.9% | |
| Sales Growth YoY %Derived | — | 17.90% | -30.60% | 25.76% | 3.86% | 3.85% | |
| Other Income | 1 | 1 ▲ 23.6% | 0 ▼ 77.6% | 1 ▲ 369.8% | 1 ▼ 7.6% | 1 ▲ 32.5% | |
| Total Income | 78 | 92 ▲ 18.0% | 63 ▼ 31.1% | 80 ▲ 26.9% | 83 ▲ 3.7% | 87 ▲ 4.2% | |
48 | 63 ▲ 32.0% | 51 ▼ 19.4% | 57 ▲ 11.9% | 54 ▼ 4.5% | 51 ▼ 5.6% | ||
| Gross ProfitDerived | 30 | 28 ▼ 4.7% | 13 ▼ 55.5% | 23 ▲ 81.4% | 28 ▲ 24.6% | 35 ▲ 21.9% | |
| Gross Margin %Derived | 38.41% | 31.06% | 19.94% | 28.77% | 34.50% | 40.49% | |
29 | 43 ▲ 46.3% | 39 ▼ 8.5% | 20 ▼ 49.6% | 24 ▲ 19.8% | 28 ▲ 17.5% | ||
| EBITDA (Operating Profit)Derived | 1 | -14 ▼ 2856.6% | -26 ▼ 84.0% | 3 ▲ 112.2% | 5 ▲ 53.5% | 7 ▲ 42.9% | |
| OPM %Derived | 0.67% | -15.77% | -41.80% | 4.05% | 5.98% | 8.23% | |
10 | 10 ▲ 2.0% | 9 ▼ 15.3% | 3 ▼ 70.4% | 3 ▲ 0.4% | 2 ▼ 7.8% | ||
| Profit Before Tax (PBT) | -9 | -24 ▼ 166.0% | -36 ▼ 49.7% | 2 ▲ 104.3% | 3 ▲ 105.3% | 6 ▲ 81.8% | |
10 | -5 ▼ 144.2% | -7 ▼ 59.7% | 0 ▲ 100.4% | 0 ▲ 576.4% | — ▼ 100.0% | ||
| Effective Tax %Derived | -115.55% | 19.19% | 20.47% | 1.67% | 5.49% | — | |
| Total Profit for Period | -19 | -19 ▲ 0.3% | -32 ▼ 64.5% | -20 ▲ 38.3% | -10 ▲ 49.1% | 25 ▲ 346.6% | |
| Less: Non-controlling Interests | — | -3 | -10 ▼ 224.9% | — ▲ 100.0% | — | — | |
| Net Profit (Owner's PAT)Derived | -19 | -16 ▲ 16.5% | -22 ▼ 33.5% | -20 ▲ 9.4% | -10 ▲ 49.1% | 25 ▲ 346.6% | |
| Net Profit Margin %Derived | -25.08% | -17.77% | -34.20% | -24.65% | -12.07% | 28.67% | |
| PAT Growth YoY %Derived | — | 16.45% | -33.52% | 9.35% | 49.13% | 346.65% | |
| Earnings Per Share (EPS ₹) | -7.38 | -6.17 ▲ 16.4% | -7.96 ▼ 29.0% | -7.46 ▲ 6.3% | -3.38 ▲ 54.7% | 8.34 ▲ 346.7% | |
| Diluted Shares Outstanding (Cr) | 3 | 3 ▲ 0.0% | 3 ▲ 0.0% | 3 ▲ 0.0% | 3 ▲ 12.2% | 3 ▲ 0.0% | |
| Share of Profit from Associates/JVs | -0 | — ▲ 100.0% | -3 | -21 ▼ 538.1% | -13 ▲ 38.5% | 19 ▲ 244.6% | |
| Other Comprehensive Income (Net of Tax) | 0 | 0 ▼ 39.4% | -0 ▼ 150.3% | -0 ▼ 31.8% | -0 ▲ 57.8% | -0 ▼ 67.8% | |
| Total Expenses (incl. D&A & Interest) | 87 | 116 ▲ 33.2% | 99 ▼ 14.4% | 79 ▼ 20.5% | 80 ▲ 1.7% | 81 ▲ 1.1% | |
| Material Cost % of RevenueDerived | 60.42% | 69.10% | 65.73% | 56.26% | 56.98% | 57.86% | |
| Employee Cost % of RevenueDerived | 18.60% | 21.03% | 27.44% | 13.26% | 15.70% | 17.68% | |
| Other Cost % of RevenueDerived | 19.14% | 25.80% | 34.30% | 11.46% | 12.82% | 14.57% | |
| Interest Coverage (x)Derived | -2.14x | -7.01x | -15.32x | 1.71x | 3.25x | 6.55x |
BROOKS LAB segment analysis : revenue and profit mix.
Disclosed business segments at BROOKS LAB with their share of revenue and profit, switchable between consolidated and standalone reporting.
BROOKS LAB discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for BROOKS LAB.
Our AI distills the core fundamental drivers supporting BROOKS LAB, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
BROOKS LAB's investment case rests on 7 positive markers and 9 flagged concerns drawn from the latest reported filings.
What you're getting.
Latest quarterly net profit increased by a substantial 498.00% to 9.58 Cr.
Robust top-line growth with quarterly sales increasing by 42.30% to 25.5 Cr.
Maintains a very healthy financial structure with a low debt-to-equity ratio of 0.08.
Promoter holding remains substantial at 52.62%, reflecting strong management confidence.
Can capitalize on the robust and expanding global healthcare market within Pharmaceuticals sector.
Key Risks.
Stock trades at a very high P/E ratio of 153.00, suggesting potential overvaluation.
Exhibits negative returns on capital employed (-9.93%), equity (-12.20%), and assets (-9.33%).
Operating profit margin (OPM) stands at a negative -3.37%, indicating core operational challenges.
Stock experienced significant price volatility, dropping from a 52-week high of 203.00.
Company currently offers a 0.00% dividend yield, deterring income-focused investors.
Flip Conditions.
Valuation risk. a P/E above 11 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 15% would indicate weaker capital compounding.
BROOKS LAB peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — BROOKS LAB is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
BROOKS LAB chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for BROOKS LAB — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
BROOKS LAB delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for BROOKS LAB over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in BROOKS LAB stood at 65.9% of traded volume, against a 20-day average of 50.1%.
BROOKS LAB announcements: results, concalls, ratings, M&A.
Filings BROOKS LAB sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
BROOKS LAB files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 50 documents below.
Shareholders meeting
Brooks Laboratories Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 03, 2026. Further, the…
Shareholders meeting
Brooks Laboratories Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 03, 2026
Copy of Newspaper Publication
Please find enclosed herewith Addendum to the Notice of 24th Annual General Meeting.
Shareholders meeting
Addendum to the Notice of 24th Annual General Meeting of the Company.
Updates
Brooks Laboratories Limited has informed the Exchange regarding 'Intimation Of Record Date, E-Voting Dates And Book Closure Date'.
Investor decks & rating reports.
BROOKS LAB dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue BROOKS LAB has declared, sequenced by announce and record date.
BROOKS LAB corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About BROOKS LAB: business, sector, key facts.
What BROOKS LAB does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
BROOKS LAB operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: BROOKS, BSE: 533543.
Brooks Laboratories Limited is a pharmaceutical company headquartered in Mumbai, India, that was established in 2002. Its primary business revolves around the manufacturing and sale of a diverse range of pharmaceutical products both domestically within India and in international markets.
The company's product portfolio encompasses a broad spectrum of dosage forms designed to cater to various medical needs. This includes liquid and dry powder injections, a specialized area focusing on carbapenem dry powder injectables, which are likely used to treat serious bacterial infections. They also produce tablets, oral suspensions (liquids taken orally), dry syrups (syrups in powder form requiring reconstitution), and ophthalmic and otic preparations (eye and ear drops respectively).
The wide variety of dosage forms suggests Brooks Laboratories caters to a broad range of therapeutic areas. While the specific therapeutic categories aren't explicitly stated, the inclusion of carbapenem injectables indicates a focus on treating severe bacterial infections, while the presence of oral and topical formulations (tablets, syrups, eye/ear drops) demonstrates a broader commitment to various treatment needs.
Brooks Laboratories' business model centers on the production and distribution of its pharmaceutical products. The company's international presence suggests a commitment to exporting its products, indicating a strategy focused on both the domestic Indian market and global markets. The success of this business likely depends on factors such as manufacturing efficiency, regulatory compliance in multiple markets, effective distribution networks, and the ongoing development of new and improved pharmaceutical formulations.
In summary, Brooks Laboratories Limited is a significant player in the Indian pharmaceutical industry, actively engaged in manufacturing and distributing a diverse range of pharmaceutical products across multiple dosage forms and likely therapeutic areas. Their international reach and focus on injectable medications, particularly carbapenems, indicate a dedication to addressing significant medical needs both within India and globally.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Losers TodayScreener
- Other undervalued NSE stocksScreener
- Quality + Value Portfolio strategyStrategy
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about BROOKS LAB (BROOKS).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of BROOKS LAB (BROOKS)?
The current share price of BROOKS LAB (BROOKS) is ₹61.02. Today, the stock has declined by ₹2.07 (3.28%), trading in a range of ₹59.13 to ₹64.70. The stock opened at ₹64.49 with a trading volume of 51,525 shares.
02Is BROOKS LAB stock a good investment for long-term?
BROOKS LAB can be considered for long-term investment based on several factors. The company has a market capitalization of ₹180.72 Cr., P/E ratio of 8.22, ROE of 20.04%, and ROCE of 5.38%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of BROOKS LAB stock?
The 52-week high price of BROOKS LAB (BROOKS) is ₹160.00, while the 52-week low is ₹36.30. Currently trading at ₹61.02, the stock is 68.1% above its 52-week low and 61.86% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy BROOKS LAB stock at the current price?
Whether to buy BROOKS LAB stock at ₹61.02 depends on multiple factors. The stock is currently trading with a P/E ratio of 8.22 and P/B ratio of 1.65. Today's performance shows a loss of 3.28%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of BROOKS LAB and when is the next dividend?
BROOKS LAB offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹61.02, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of BROOKS LAB?
BROOKS LAB's key financial metrics include: P/E Ratio: 8.22, P/B Ratio: 1.65, ROE: 20.04%, ROCE: 5.38%, Dividend Yield: 0%, EPS: ₹4.49, Book Value: ₹41.64, and Debt-to-Equity: 0.06. The company's market cap stands at ₹180.72 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is BROOKS LAB stock performing today in the market?
BROOKS LAB stock opened at ₹64.49 and is currently trading at ₹61.02, showing a decline of ₹2.07 (3.28%). The intraday high is ₹64.70 and low is ₹59.13. The trading volume stands at 51,525 shares, indicating moderate market participation today.
08What is the P/E ratio of BROOKS LAB and what does it indicate?
BROOKS LAB has a Price-to-Earnings (P/E) ratio of 8.22, which means investors are willing to pay 8.22 for every ₹1 of earnings. With an EPS of ₹4.49, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about BROOKS LAB (BROOKS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.